DHR
Danaher CorporationHealthcare · $156.4B market cap
Verdict
Share price
$214.06
close of Oct 3, 2026
Fair value
$123.17
Sticker Price
Payback Price
$49.27
buy price
DHR is Overpriced: at $214.06 it trades 74% above its fair value of $123.17. Its buy price (Payback Price) is $49.27, 77% below today's price. Business quality is limited: none of the 5 key numbers clears the 10% bar.
How we valued it
Free Cash Flow. Sales grew -3% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow DHR
Get notified when it reaches its buy price of $49.27. Free.
Create a free accountSuperinvestors
11 of the investors we track hold DHR. In Q2 2026, 2 opened a position, 1 added and 1 sold out. Who we track
Pat Dorsey
Dorsey Asset Management · as of Q2 2026
$119.3M
626,211 shares
First Pacific Advisors
First Pacific Advisors · as of Q2 2026
$107.6M
564,781 shares
Daniel Loeb
Third Point · as of Q2 2026
$102.9M
540,000 shares
Wallace Weitz
Weitz Investment Management · as of Q2 2026
$93.2M
489,500 shares
Chase Coleman
Tiger Global Management · as of Q2 2026
$86.9M
456,000 shares
Show all 11 holdersShow fewer
Bill & Melinda Gates Foundation Trust
Bill & Melinda Gates Foundation Trust · as of Q2 2026
$71.0M
373,000 shares
Dodge & Cox Funds
Dodge & Cox Funds · as of Q2 2026
$49.0M
257,039 shares
Torray Funds
Torray Funds · as of Q2 2026
$356K
1,871 shares
Bill Nygren
Oakmark Funds · as of Q2 2026
$350K
1,838 shares
David Katz
Matrix Asset Advisors · as of Q2 2026
$320K
1,681 shares
Mairs & Power Funds
Mairs & Power Funds · as of Q2 2026
$218K
1,142 shares
Moves in Q2 2026
New position: First Pacific Advisors, Chase Coleman
Added: Dodge & Cox Funds
Sold out: Lee Ainslie
Insider activity
Since Jul 15, 2026: no open-market purchases, 3 sales worth $12.7M and 23 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Blair Rainer
President & CEO · 2026-08-21
Sold
$1.7M
Blair Rainer
President & CEO · 2026-08-21
Sold
$8.6M
Blair Rainer
President & CEO · 2026-08-21
Sold
$2.5M
Other filings
RALES STEVEN M
Chairman · 2026-08-04
Award
$194.8M
RALES STEVEN M
Chairman · 2026-08-04
Award
500,000 shares
RALES MITCHELL P
Chairman of Exec. Committee · 2026-08-04
Award
500,000 shares
RALES MITCHELL P
Chairman of Exec. Committee · 2026-08-04
Award
$194.8M
Bouda Christopher
VP, Chief Accounting Officer · 2026-08-04
Award
$2.4M
Show all 23 other filingsShow fewer
Sawyer Montgomery Julie A
Executive Vice President · 2026-08-04
Award
$47.9M
Leiken Jonathan
SVP-Chief Legal Officer · 2026-08-04
Award
$17.9M
Milosevich Gregory M
Executive Vice President · 2026-08-04
Award
15,402 shares
Gutierrez-Ramos Jose-Carlos
SVP, Chief Science Officer · 2026-08-04
Award
13,477 shares
Gugino Matthew E
EVP & Chief Financial Officer · 2026-08-04
Award
$29.9M
Riley Christopher Paul
Executive Vice President · 2026-08-04
Award
41,072 shares
Stevens Raymond C
director · 2026-07-31
Award
181.549 shares
Dewan Feroz
director · 2026-07-31
Award
171.195 shares
Sanders A Shane
director · 2026-07-31
Award
211.205 shares
List Teri
director · 2026-07-31
Award
15.716 shares
SPOON ALAN G
director · 2026-07-31
Award
229.896 shares
Zerhouni Elias A.
director · 2026-07-31
Award
236.633 shares
FILLER LINDA
director · 2026-07-31
Award
18.333 shares
Zerhouni Elias A.
director · 2026-07-15
Tax withholding
$237K
Zerhouni Elias A.
director · 2026-07-15
Option exercise
$237K
FILLER LINDA
director · 2026-07-15
Tax withholding
$237K
FILLER LINDA
director · 2026-07-15
Option exercise
$237K
Bouda Christopher
VP, Chief Accounting Officer · 2026-07-15
Tax withholding
$12K
About Danaher Corporation
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment…
Medical - Diagnostics & Research
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works